Literature DB >> 21382192

Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.

Michael C Dobelbower1, Omer L Burnett Iii, Robert A Nordal, Louis B Nabors, James M Markert, Mark D Hyatt, John B Fiveash.   

Abstract

PURPOSE: To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide.
MATERIALS AND METHODS: A retrospective review of patients treated with concurrent radiation and temozolomide was performed. Twenty patients treated at the University of Alabama at Birmingham, with biopsy-proven disease, documented disease progression after treatment, and adequate radiation dosimetry and imaging records were included in the study. Patients generally received 46 Gy to the primary tumour and surrounding oedema plus 1 cm, and 60 Gy to the enhancing tumour plus 1 cm. MRIs documenting failure after therapy were fused to the original treatment plans. Contours of post-treatment tumour volumes were generated from MRIs showing tumour failure and were overlaid onto the original isodose curves. The recurrent tumours were classified as in-field, marginal or regional. Recurrences were also evaluated for distant failure.
RESULTS: Of the 20 documented failures, all patients had some component of failure at the primary site. Eighteen patients (90%) failed in-field, 2 patients (10%) had marginal failures, and no regional failures occurred. Four patients (20%) had a component of distant failure in which an independent satellite lesion was located completely outside of the 95% isodose curve.
CONCLUSIONS: Radiation concurrent with temozolomide appears to be associated with a moderate risk of distant brain failure in addition to the high rate of local failure. The risk of distant failure was consistent with that observed with radiation alone, suggesting that temozolomide does not act to reduce distant brain failure but to improve local control.
© 2011 The Authors. Journal of Medical Imaging and Radiation Oncology © 2011 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382192     DOI: 10.1111/j.1754-9485.2010.02232.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  33 in total

Review 1.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

2.  Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.

Authors:  Andrew Elson; Eric Paulson; Joseph Bovi; Malika Siker; Chris Schultz; Peter S Laviolette
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

3.  Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Matteo Simonelli; Armando Santoro; Elena Clerici; Marco Rossi; Marta Scorsetti; Lorenzo Bello
Journal:  J Neurooncol       Date:  2017-07-08       Impact factor: 4.130

4.  An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma.

Authors:  Edward White; Alison Bienemann; John Pugh; Emma Castrique; Marcella Wyatt; Hannah Taylor; Alan Cox; Cameron McLeod; Steven Gill
Journal:  J Neurooncol       Date:  2012-04-04       Impact factor: 4.130

5.  Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.

Authors:  Kevin Petrecca; Marie-Christine Guiot; Valerie Panet-Raymond; Luis Souhami
Journal:  J Neurooncol       Date:  2012-10-10       Impact factor: 4.130

6.  Synergistic chemotherapy by combined moderate hyperthermia and photochemical internalization.

Authors:  Catherine Christie; Stephanie Molina; Jonathan Gonzales; Kristian Berg; Rohit Kumar Nair; Khoi Huynh; Steen J Madsen; Henry Hirschberg
Journal:  Biomed Opt Express       Date:  2016-03-14       Impact factor: 3.732

7.  Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?

Authors:  Michela Buglione; Sara Pedretti; Pietro Luigi Poliani; Roberto Liserre; Stefano Gipponi; Giannantonio Spena; Paolo Borghetti; Ludovica Pegurri; Federica Saiani; Luigi Spiazzi; Giulia Tesini; Chiara Uccelli; Luca Triggiani; Stefano Maria Magrini
Journal:  J Neurooncol       Date:  2016-03-30       Impact factor: 4.130

Review 8.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

9.  Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma.

Authors:  Anna K Paulsson; Jordan A Holmes; Ann M Peiffer; Lance D Miller; Wennuan Liu; Jianfeng Xu; William H Hinson; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Waldemar Debinski; Michael D Chan
Journal:  J Neurooncol       Date:  2014-07-03       Impact factor: 4.130

10.  Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.

Authors:  Anna K Paulsson; Kevin P McMullen; Ann M Peiffer; William H Hinson; William T Kearns; Annette J Johnson; Glenn J Lesser; Thomas L Ellis; Stephen B Tatter; Waldemar Debinski; Edward G Shaw; Michael D Chan
Journal:  Am J Clin Oncol       Date:  2014-04       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.